GLOBAL – Oatside, A Singaporean oat milk brand, is leading this week’s food startup investment round up having successfully completed a US$65 million series A funding round.

The new funding was co-led by Temasek Holdings and GGV Capital as well as Arabica International, and existing investors Wee Teng Wen and Proterra Investment Partners Asia.

The funding will help Oatside expand its production and increase reach across Singapore and the greater Asia-Pacific region.

Oatside’s successful funding round comes at a time when Israel is emerging as the new hub for vegan and alternative protein startups.

According to a report by the Good Food Institute, the Middle Eastern country attracted US$200 million as of the end of June, making it the world leader in alternative protein funding by percentage.

“The next few years will determine the Israeli ecosystem’s long term position in the future of our global food system. Can it sustain its leadership? Will it leverage it and become an industrial leader as well and promote Israeli national food security?” wrote Nir Goldstein, Managing Director of GFI Israel.

Changing Biotech lead’s Chinese foray into precision fermentation for dairy

Meanwhile in China, Changing Biotech is leading the country’s foray into precision fermentation. The startup which uses precision fermentation to produce milk protein recently raised US$22 million in a Series A led by veteran domestic agtech venture capital fund Bits x Bites.

Changing Biotech has a five-ton test facility in Qingdao that is already producing single-cell milk protein which can be used for all sorts of applications, from milk to chocolate to snacks.

The funding will support Changing Biotech’s plans to build a 9,000-square-meter plant as well as the installation of six new 50-ton lines.

As per Green Queen‘s reporting, this funding round would be the largest for China’s alternative protein industry after plant-based meat maker Starfield’s US$100 million Series B announced this past January.

Cotswolds distillery & CBD brand Trip raise funds for expansion

Moving away from alternative protein funding, UK-based Cotswolds distillery has raised £3m funding from Santander to ramp up its production of English whisky and gin.

The funding will be used to support business liquidity, enabling it to lay down additional stock to meet future demand, improve production efficiencies, and bolster its status as an English whisky producer.

Meanwhile, Trip, a UK-based CBD brand, has raised $12 million in funding, as it looks to continue its growth in the US market and beyond.

The round was supported by entrepreneurs, business leaders and investors, including Maria Raga, former CEO of Depop, and Christian Angermeyer, founder of Apeiron Investment Group.

The brand will use the investment to expand its retail footprint through strategic partnerships in the US, including becoming Soho House & Co’s exclusive global CBD supplier as well as Los Angeles-based retailer, Erewhon.